Search Results
Feb 25, 2026, 04:00 ET SteinCares and Shilpa Biologicals Strike into Licensing Agreement to Expand Access to Biosimilars Across Latin America
pioneering biosimilar therapies.About Shilpa BiologicalsShilpa Biologicals is an integrated biopharmaceutical company with a hybrid CDMO model. It offers development, manufacturing, and ready-to-license formulations in immunology, oncology, and ophthalmics.Logo:
More news about: Shilpa Medicare Limited
Feb 25, 2026, 03:22 ET SteinCares và Shilpa Biologicals ký kết thỏa thuận cấp phép nhằm mở rộng khả năng tiếp cận thuốc sinh học tương tự trên khắp khu vực Mỹ Latinh
pháp sinh học tương tự.Giới thiệu về Shilpa BiologicalsShilpa Biologicals là một công ty dược phẩm sinh học tích hợp với mô hình CDMO kết hợp. Công ty cung cấp dịch vụ phát triển, sản xuất và các công thức sẵn sàng cấp phép trong lĩnh vực miễn dịch học, ung thư học và nhãn khoa.Logo:
More news about: Shilpa Medicare Limited
Feb 25, 2026, 03:00 ET SteinCares und Shilpa Biologicals schließen Lizenzvereinbarung zur Erweiterung des Zugangs zu Biosimilars in ganz Lateinamerika
ein.Informationen zu Shilpa BiologicalsShilpa Biologicals ist ein integriertes biopharmazeutisches Unternehmen mit einem hybriden CDMO-Modell. Das Unternehmen bietet Entwicklung, Herstellung und lizenzierfertige Formulierungen in den Bereichen Immunologie, Onkologie und Ophthalmologie.Logo:
More news about: Shilpa Medicare Limited
Feb 25, 2026, 03:00 ET SteinCares et Shilpa Biologicals concluent un accord de licence pour élargir l'accès aux biosimilaires en Amérique latine
thérapies biosimilaires.À propos de Shilpa BiologicalsShilpa Biologicals est une société biopharmaceutique intégrée dotée d'un modèle CDMO hybride. Elle propose le développement, la fabrication et des formulations prêtes à l'emploi dans les domaines de l'immunologie, de l'oncologie et de
More news about: Shilpa Medicare Limited
Feb 24, 2026, 20:15 ET Avid Bioservices gibt die Eröffnung seines neuen Kompetenzzentrums für die frühe Phase in Costa Mesa, Kalifornien, bekannt
COSTA MESA, Kalifornien, 25. Februar 2026 /PRNewswire/ -- Avid Bioservices, Inc., ein spezialisierter CDMO-Anbieter für Biologika, gab heute die Eröffnung seines neuen Early Phase Center of Excellence bekannt, einer hochmodernen, 78.000 Quadratfuß großen
More news about: Avid Bioservices
Feb 24, 2026, 10:08 ET Cellipont Bioservices and Soter Bio Announce Strategic Collaboration to Support Integrated U.S. Cell Therapy Manufacturing
Manufacturing Organization (CDMO), today announced a strategic collaboration with Soter Bio, a CDMO specializing in RNA and
More news about: Cellipont Bioservices
Feb 24, 2026, 10:02 ET Avid Bioservices annonce l'ouverture d'un nouveau centre d'excellence pour les phases précoces à Costa Mesa, en Californie
COSTA MESA, Calif., 24 février 2026 /PRNewswire/ -- Avid Bioservices, Inc., une CDMO spécialisée dans les produits biologiques, a annoncé aujourd'hui l'ouverture officielle de son nouveau Centre d'excellence pour les phases précoces,
More news about: Avid Bioservices
Feb 24, 2026, 09:04 ET C-Ray Therapeutics Achieves AAALAC International Full Accreditation, Reinforcing Commitment to Excellence in Preclinical Research
Actinium-225.To date, the company has successfully delivered over 70 CRDMO projects, including 50 preclinical and molecular imaging CRO projects and 24 CDMO projects. Among these achievements, the company has supported 5 programs through IND and IND-enabling stages, facilitated 16 investigator-initiated
More news about: C Ray Therapeutics
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
ON, Feb. 24, 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01)
ON, Feb. 24, 2026 /PRNewswire/ - AtomVie Global Radiopharma (AtomVie), a global leading radiopharmaceutical CDMO, announced that it has supplied the successful dosing of the first patient in Radiopharm Theranostics' First-in-Human Phase 1/2a clinical study of 177Lu‑BetaBart
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma liefert erste Patientendosis in Phase 1/2a der klinischen Studie von Radiopharm Theranostics mit 177Lu-BetaBart (RV-01)
24.Februar 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), ein weltweit führendes radiopharmazeutisches CDMO, gab bekannt, dass es die erfolgreiche Dosierung des ersten Patienten in der klinischen First-in-Human-Phase 1/2a-Studie von Radiopharm Theranostics
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma suministra la primera dosis en el estudio clínico de Radiopharm Theranostics
HAMILTON, ON, 24 de febrero de 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), un CDMO radiofarmacéutico líder a nivel mundial, anunció que ha suministrado la dosificación exitosa del primer paciente en el estudio clínico de Fase 1/2a
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 09:00 ET AtomVie Global Radiopharma fournit la première dose à un patient dans le cadre de l'étude clinique de phase 1/2a de Radiopharm Theranostics sur le 177Lu-BetaBart (RV-01)
HAMILTON, ON, 24 février 2026 /PRNewswire/ -- AtomVie Global Radiopharma (AtomVie), une CDMO radiopharmaceutique de premier plan au niveau mondial, a annoncé qu'elle a fourni le dosage réussi du premier patient de l'étude clinique de phase 1/2a
More news about: AtomVie Global Radiopharma Inc.
Feb 24, 2026, 08:05 ET Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California
COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of the art 78,000 square foot facility located in Costa Mesa,
More news about: Avid Bioservices
Feb 24, 2026, 08:05 ET Avid Bioservices Announces Grand Opening of New Early Phase Center of Excellence in Costa Mesa, California
COSTA MESA, Calif., Feb. 24, 2026 /PRNewswire/ -- Avid Bioservices, Inc., a dedicated biologics CDMO, today announced the grand opening of its new Early Phase Center of Excellence, a state of the art 78,000 square foot facility located in Costa Mesa,
More news about: Avid Bioservices
Feb 24, 2026, 08:05 ET Avid Bioservices anuncia inauguración del Centro de Excelencia de Fase Temprana en Costa Mesa, California
febrero de 2026 /PRNewswire/ -- Avid Bioservices, Inc., una empresa de desarrollo de productos biológicos (CDMO), anunció hoy la inauguración de su nuevo Centro de Excelencia de Fase Temprana, unas instalaciones de vanguardia de 78.000 pies cuadrados ubicadas en
More news about: Avid Bioservices
Feb 24, 2026, 02:59 ET Akums fortalece su presencia en Europa y Reino Unido: la mayor CDMO de la India amplía su presencia global
Akums Drugs & Pharmaceuticals Ltd., la mayor CDMO de la India, ha obtenido la certificación de Buenas Prácticas de Fabricación de la Unión Europea (EU GMP) para dos de sus instalaciones de fabricación
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 24, 2026, 02:58 ET Akums verstärkt Präsenz in Europa und Großbritannien - Indiens größter CDMO erweitert globale Reichweite
2026 /PRNewswire/ -- Akums Drugs & Pharmaceuticals Ltd., Indiens größter CDMO, hat die Zertifizierung nach der Guten Herstellungspraxis der Europäischen Union (EU GMP) für zwei seiner Produktionsanlagen in Indien erhalten und stärkt
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 24, 2026, 02:56 ET Akums renforce sa présence en Europe et au Royaume-Uni - Le plus grand CDMO d'Inde étend sa présence à travrs le monde
2026 /PRNewswire/ -- Akums Drugs & Pharmaceuticals Ltd, le plus grand CDMO de l'Inde, a obtenu la certification des bonnes pratiques de fabrication de l'Union européenne (BPF de l'UE) pour deux de ses centres de fabrication
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 23, 2026, 06:32 ET Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
2026 /PRNewswire/ -- Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities located in India, reinforcing
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 23, 2026, 06:29 ET Akums Strengthens European and UK Presence -- India's Largest CDMO Expands Global Footprint
/PRNewswire/ -- Akums Drugs & Pharmaceuticals Ltd., India's largest CDMO, has secured European Union Good Manufacturing Practice (EU GMP) certification for two of its manufacturing facilities located in India, reinforcing
More news about: Akums Drugs & Pharmaceuticals Ltd
Feb 20, 2026, 10:01 ET Amino Acids Market to Surpass USD 56.3 Billion by 2032, Reveals New Maximize Market Research Analysis
and Oligonucleotide CDMO Market: https://www.maximizemarketresearch.com/market-report/peptide-and-oligonucleotide-cdmo-market/188510/Amino Acid
More news about: Maximize Market Research Pvt. Ltd.
Feb 19, 2026, 14:46 ET Cambrex 宣佈 Cornell 教授 Song Lin 榮獲 2025 年 Snapdragon 化學技術創新獎
新澤西州東拉瑟福2026年2月20日 /美通社/ -- 全球領先的合約研究開發與製造組織 (CDMO) Cambrex 及其旗下公司 Snapdragon Chemistry 欣然宣佈，Cornell University 文理學院化學與化學生物學的 Tisch University 教授 Song Lin 博士榮獲 2025 年 Snapdragon 化學技術創新獎 (Snapdragon Prize for Innovation in Chemistry
More news about: Cambrex
Feb 19, 2026, 14:07 ET A Cambrex anuncia o professor Song Lin, da Universidade Cornell, como vencedor do Prêmio Snapdragon de Inovação em Tecnologia Química de 2025
19 de fevereiro de 2026 /PRNewswire/ -- A Cambrex, organização líder global de desenvolvimento e fabricação por contrato (CDMO) e a Snapdragon Chemistry, uma empresa da Cambrex, têm o orgulho de anunciar que o Dr. Song Lin, professor da Universidade Tisch em química e biologia
More news about: Cambrex
Feb 19, 2026, 14:03 ET Cambrex gibt Cornell-Professor Song Lin als Preisträger des Snapdragon-Preises 2025 für Innovation in der Chemietechnik bekannt
19. Februar 2026 /PRNewswire/ -- Cambrex, ein weltweit führender Anbieter für Auftragsentwicklung und -herstellung (CDMO), sowie Snapdragon Chemistry, ein Unternehmen von Cambrex, gaben heute bekannt, dass Dr. Song Lin, Tisch University Professor für Chemie und chemische
More news about: Cambrex